Company Reports

Sartorius Stedim Biotech, a subsidiary of Sartorius AG, is a leading provider of bioprocessing equipment and consumables. It offers a comprehensive portfolio that spans the full spectrum of upstream and downstream processes required for biologics manufacturing. Its ability to deliver end-to-end solutions and focus as a pure-play biopharmaceutical equipment supplier distinguish SSB from more-diversified competitors. The company reinforces its competitive edge by leading the market in bioreactors, a core component of the biomanufacturing process.

Sartorius Stedim reported second-quarter results with 8% organic sales growth, excluding tariff surcharge compensation and currency effects, and underlying EBITDA margin expanding to 32.1% from 31.3% year over year. Management confirmed its full-year guidance.

Sartorius Stedim reported first-quarter constant-currency sales growth of 7.9%, with both segments contributing healthy numbers. Underlying EBITDA margin declined 10 basis points to 30.7%. Management confirmed its full-year guidance.

Sartorius Stedim Biotech, a subsidiary of Sartorius AG, is a leading provider of bioprocessing equipment and consumables. It offers a comprehensive portfolio that spans the full spectrum of upstream and downstream processes required for biologics manufacturing. Its ability to deliver end-to-end solutions and focus as a pure-play biopharmaceutical equipment supplier distinguish SSB from more-diversified competitors. The company reinforces its competitive edge by leading the market in bioreactors, a core component of the biomanufacturing process.

Life science stocks have been under pressure since late 2022, but with profits expected to rebound in the high single digits in 2026 on average and potentially accelerate even further in 2027-30 due to upcoming catalysts, we see growing momentum in the industry’s profit growth trajectory.

Sartorius Stedim reported its preliminary full-year 2025 results with 9.6% growth in constant currencies and in line with company-compiled consensus, while the adjusted EBITDA margin of 30.8% fell short.

Sartorius Stedim Biotech, a subsidiary of Sartorius AG, is a leading provider of bioprocessing equipment and consumables. It offers a comprehensive portfolio that spans the full spectrum of upstream and downstream processes required for biologics manufacturing. Its ability to deliver end-to-end solutions and focus as a pure-play biopharmaceutical equipment supplier distinguish SSB from more-diversified competitors. The company reinforces its competitive edge through market leadership in bioreactors, which are core components of the biomanufacturing process.

Sartorius Stedim Biotech reported third-quarter results, with both sales and adjusted EBITDA beating company-compiled consensus. Sales increased 12% in constant currency, while underlying EBITDA increased 24.6%. The shares traded as much as 12% higher intraday.

Sartorius Stedim Biotech reported its second-quarter 2025 results, where the revenue miss was offset by an underlying EBITDA beat against company-compiled consensus. Sales increased 8.4% in constant currency, while underlying EBITDA increased by 18.7%. Shares are trading 10% lower intraday.

We are transferring coverage of Sartorius AG and its subsidiary Sartorius Stedim Biotech—both active in biopharmaceutical equipment and laboratory consumables—to a new analyst. Sartorius Stedim Biotech accounts for approximately 80% of group revenue and 89% of EBIT.

Sartorius Stedim Biotech, a subsidiary of Sartorius AG, is a leading provider of bioprocessing equipment and consumables. It offers a comprehensive portfolio that spans the full spectrum of upstream and downstream processes required for biologics manufacturing. Its ability to deliver end-to-end solutions and focus as a pure-play biopharmaceutical equipment supplier distinguish SSB from more-diversified competitors. The company reinforces its competitive edge through market leadership in bioreactors, which are core components of the biomanufacturing process.

Sartorius Stedim Biotech reported its first-quarter 2025 results, exceeding company-compiled consensus estimates. Sales and adjusted EBITDA increased in constant currency by 10.4% and 19.9%, respectively. Shares are trading 4% higher intraday.

Over the past week, life science shares have experienced significant volatility related to a deepening trade war with China and as broader US tariffs were implemented and then paused for 90 days to allow time for negotiations. A pharmaceutical-specific tariff is also being considered.

Wide-moat Sartorius AG and its bioprocessing subsidiary wide-moat Sartorius Stedim Biotech reported third-quarter earnings broadly in line with our expectations, but more pertinently management signalled an imminent end to the customer destocking that has weighed on sentiment and fuelled uncertainty. This comes after they revised full-year guidance downward at the midyear results, citing an uncertain recovery time line. Both companies’ shares are trading up over 15% intraday as a result. With no changes to our forecasts, we maintain our fair value estimates of EUR 265 and EUR 215 for Sartorius AG preference shares and Sartorius Stedim, respectively.

Wide-moat Sartorius AG and its bioprocessing subsidiary wide-moat Sartorius Stedim Biotech, or SSB, reported second-quarter earnings that were in line with our expectations. However, the companies revised their full-year guidance downward, based on slow and uncertain recovery momentum. We pushed out our post-covid recovery trajectories by one year and lowered our midterm growth forecasts to reflect a slowdown in China. For Sartorius AG preference shares, we lowered our fair value estimate to EUR 265 from EUR 295. For Sartorius Stedim, we lowered our fair value estimate to EUR 215 from EUR 240. We think the long-term story remains intact and currently view the shares as undervalued, but acknowledge that the near-term outlook is uncertain.

Sartorius Stedim Biotech, the bioprocess subsidiary of Sartorius AG, is a leading provider of single-use biopharmaceutical fermentation and fluid management solutions. Sartorius performs consultations and custom installations of biomanufacturing systems for its drugmaker clients, which include bioreactors, filtration and purification systems, and cell analysis systems. This equipment has high disposable consumable requirements, including single-use bioreactor bags, filters, tubes, and containers. The company’s proven expertise in single-use technology, or SUT, and the regulation-validated nature of biomanufacturing gives Sartorius an attractive razor-and-blades model and supports a wide economic moat.

Wide-moat Sartorius and its bioprocessing subsidiary Sartorius Stedim Biotech, or SSB, reported first-quarter earnings that were a modest disappointment to us, with revenue mildly lower than our forecast. However, we continue to see early signs of recovery in the order books, and think that the company is still on track to meet its full-year guidance. We are maintaining our fair value estimates of EUR 295 per Sartorius AG preference share and EUR 240 per SSB share, and we view the current prices as slightly cheap with a slight preference for SSB.

Wide-moat companies Sartorius AG and its bioprocessing subsidiary Sartorius Stedim Biotech, or SSB, reported preliminary full-year results that were slightly below expectations. More significantly, the companies provided midterm guidance out until 2028 that were in line with expectations. We maintain our fair value estimates of EUR 295 per Sartorius AG preference share and EUR 240 per SSB share, and view the current prices as fairly valued.

We are transferring coverage of Sartorius AG and its bioprocessing subsidiary Sartorius Stedim Biotech, or SSB. We maintain our wide moat ratings for both companies due to the high regulatory hurdles of validated biomanufacturing and Sartorius’ excellent reputation for single-use technologies. However, we are reducing our fair value estimates on both companies due to our higher long-term cost of sales assumptions. For Sartorius AG, we revise our fair value downward to EUR 295 per preference share from EUR 315 previously. For SSB, we revise our fair value to EUR 240 per share from EUR 287.

Sartorius Stedim Biotech, the bioprocess subsidiary of Sartorius AG, is a leading provider of single-use biopharmaceutical fermentation and fluid management solutions. Sartorius performs consultations and custom installations of biomanufacturing systems for its drugmaker clients, which include bioreactors, filtration and purification systems, and cell analysis systems. This equipment has high disposable consumable requirements, including single-use bioreactor bags, filters, tubes, and containers. The company’s proven expertise in single-use technology, or SUT, and the regulation-validated nature of biomanufacturing gives Sartorius an attractive razor-and-blades model and supports a wide economic moat.